Abstract
The 2023 Precision Oncology Summit was organized by Binaytara foundation in San Francisco on October 7th and 8th. The theme of the conference was to discuss the recent advances in precision oncology and future directions to move away from a one-size-fits-all model in order to improve patient outcomes. This manuscript reviews the session on precision oncology in solid tumors. The first lecture during this session was on tumor-agnostic FDA approvals delivered by Peter J. O’Dwyer, M.D., whereas the second lecture by Pauline Funchain, M.D., discussed melanoma as a paradigm for precision immuno-oncology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
